Literature DB >> 7711414

A case of pure red cell aplasia: follow-up on different immunosuppressive regimens.

M Baldus1, M Möller, H Walter, H Brass, W Queisser.   

Abstract

A 66-year-old patient was admitted to our hospital in January 1992 for further evaluation of severe normocytic anemia. Hemoglobin (Hb) was 3.5 g/dl, reticulocyte count 1%. Bone marrow showed a nearly complete lack of red cell precursors, thus favoring the diagnosis of acquired pure red cell aplasia (PRCA). Immunosuppressive therapy with prednisolone was started but had to be supplemented with azathioprine because of a further rapid decrease in Hb to 3.7 g/dl after an initial transfusion of 6 U red blood cells. However, with this regimen a renewed decrease in Hb to 6.6 g/dl was noted, and further transfusions were required. Therefore therapy was switched to cyclosporine A (CyA) while tapering off prednisolone. Four months after the initial diagnosis a positive parvovirus B19 IgM antibody was found. After the failure of hematological remission with three immunosuppressive regimens a course of high-dose intravenous immunoglobulins (IVIG) was administered in July 1992. Six weeks after IVIG therapy a peak hemoglobin concentration of 12.3 g/dl was noted, and further transfusion was not required. CyA was tapered off in October 1992. One month later CyA was reinstituted because of a relapse of PRCA but was unsuccessful until January 1993. At this time immunosuppressive CyA therapy was discontinued because of a periodontal abscess. In February 1993 a second IVIG infusion was given, and a second remission of PRCA was noted, showing an increase in hemoglobin up to 14.5 g/dl by November 1993. At the last follow-up visit in February 1994 our patient was still in complete hematological remission.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711414     DOI: 10.1007/bf00577754

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  29 in total

1.  Prevalence of antibodies to parvovirus B19 in selected groups of patients and healthy individuals.

Authors:  T F Schwarz; B Hottenträger; M Roggendorf
Journal:  Zentralbl Bakteriol       Date:  1992-02

2.  Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction.

Authors:  F McOmish; P L Yap; A Jordan; H Hart; B J Cohen; P Simmonds
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

Review 3.  Pure red cell aplasia in childhood and adolescence: pathogenesis and approaches to diagnosis.

Authors:  M H Freedman
Journal:  Br J Haematol       Date:  1993-10       Impact factor: 6.998

Review 4.  [Hematological significance of parvovirus B19 infection].

Authors:  T F Schwarz; G Jäger
Journal:  Dtsch Med Wochenschr       Date:  1993-06-11       Impact factor: 0.628

5.  [High-dose immunoglobulin therapy of aplastic syndrome].

Authors:  H Bodenstein
Journal:  Infusionsther Transfusionsmed       Date:  1993-04

6.  Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response.

Authors:  R T Means; E N Dessypris; S B Krantz
Journal:  Br J Haematol       Date:  1991-05       Impact factor: 6.998

7.  Human parvovirus infection in homozygous sickle cell disease.

Authors:  G R Serjeant; B E Serjeant; P W Thomas; M J Anderson; G Patou; J R Pattison
Journal:  Lancet       Date:  1993-05-15       Impact factor: 79.321

8.  Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies.

Authors:  K McClain; Z Estrov; H Chen; D H Mahoney
Journal:  Br J Haematol       Date:  1993-09       Impact factor: 6.998

9.  Immunophenotyping of fetal haemopoietic cells permissive for human parvovirus B19 replication in vitro.

Authors:  A L Morey; K A Fleming
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

10.  Complete remission in pure red cell aplasia after plasmapheresis.

Authors:  L G Freund; E Hippe; S Strandgaard; L M Pelus; A J Erslev
Journal:  Scand J Haematol       Date:  1985-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.